Clinical study I culture a heart stem cell and go back up to myocardium, and to strengthen a function（心臓幹細胞を培養し、心筋に戻して機能を強化する臨床研究）

The Masaru Okayama Hospital cultured the heart stem cell of the infant who had an abnormality in heart by nature on 23rd, and a clinical study I returned it to the myocardium, and to strengthen a function clarified a successful thing. Seven myocardial performances that I put treatment for by "regenerative medicine" to transplant own stem cell with the replication competence that I worked on ahead of the world from last March are up to 22% of improvement from 5%. The treatment team applies to the country for "the high medical care" in July and steps forward to the one step to "normal medical care" becoming the insurance application.

A patient losing a cure has few "only heart transplants", but, in the case of congenital heart disease, the brain-dead donor (donor) of the infant finally hardly appears.
Because "I strengthen cardiac function, and the possibility that it is undergone a heart transplant if I bring up a body rises", this success is expected when it is in a new choice of the treatment.
Because this treatment got the approval of the country as a study to check safety and an effect, and carried it out; only seven patients. After having got approval in Masaru Okayama Ethical Review Board, the treatment team applies to "altitude medical care" (insurance inappropriate business, up to 40) to inspect an effect more. I aim at the complete application through "the advanced medical care" that a part of the treatment costs becomes the insurance application in the future. It wants you usually to receive it as medical care by all means. I want you to push forward a further clinical study.



岡山大病院は23日、生まれつき心臓に異常がある小児の心臓幹細胞を培養し、心筋に戻して機能を強化する臨床研究が成功したことを明らかにした。昨年３月から世界に先駆けて取り組んできた、複製能力のある自らの幹細胞を移植する「再生医療」で、治療を施した７人の心筋機能は５％から最大22％改善。治療チームは７月にも国に「高度医療」の申請をし、保険適用となる“通常の医療”への一歩を踏み出す。
　先天性心疾患の場合、最終的には「心臓移植」しか治療法がなくなる患者は少なくないが、小児の脳死ドナー（臓器提供者）はほとんど現れない。
「心機能を強化し、身体を成長させれば心臓移植を受けられる可能性が増す」ため、今回の成功は治療の新たな選択肢になると期待されている。
　今回の治療は安全性と効果を確かめる研究として国の承認を得て実施したため、患者は７人のみ。治療チームは岡山大倫理委員会で承認を得た後、さらに効果を検証する「高度医療」（保険不適用、最大40人）に申請。将来的には、治療費の一部が保険適用となる「先進医療」を経て完全適用を目指す。ぜひ、通常医療として受けられるようにして欲しいですね。更なる臨床研究を進めて欲しいですね。